Navigation Links
Vivo Ventures Closes $375 Million 7th Fund to Invest in Healthcare in the U.S. and Greater China
Date:1/3/2012

PALO ALTO, Calif., Jan. 3, 2012 /PRNewswire/ -- Vivo Ventures, a healthcare investment firm with offices in Palo Alto, California, Shanghai, and Chengdu, China, announced the final closing of Vivo Ventures VII ("Vivo VII") at $375 million, which brings the firm's total funds under management to more than $1 billion.

Vivo plans to invest the capital primarily in later development stage pharmaceutical and medical device companies in the U.S. and in revenue stage healthcare companies in greater China.  As an early entrant to the Chinese healthcare market, Vivo plans to continue assisting companies in both countries in their efforts to forge cross-border partnerships, enabling companies to acquire new products and expand the market for their existing products.  Vivo also intends to continue its successful strategies of building companies from scratch, identifying later stage products with a high probability of FDA approval, and investing directly in public companies.

Vivo's recent IPOs and exits include Sagent (IPO, Nasdaq), China Kanghui (IPO, NYSE), Vicept (acquired by Allergan), Bioform (acquired by Merz), as well as investments in Avanir Pharmaceuticals (Nasdaq), Acura Pharmaceuticals (Nasdaq), Lee's Pharm (HKEx), and Achillion Pharmaceuticals (Nasdaq).

The managing partners of Vivo VII are Drs. Frank Kung, Albert Cha, Edgar Engleman, Chen Yu, and James Zhao. Investors in the Vivo VII include pension funds, funds of funds, university endowments, foundations, financial institutions, and family offices. In addition to limited partners that participated in Vivo's earlier funds, Vivo VII added a number of new institutional investors from the U.S., Europe, and Asia.

About Vivo Ventures

Founded in 1996, Vivo Ventures is a healthcare investment firm focused on investing in and building high quality companies in the U.S. and China.  With more than $1 billion under management, Vivo employs a unique multi-pronged strategy of identifying and working with companies with promising later development stage products in the U.S. and revenue stage companies in China.   Vivo Ventures (http://www.vivoventures.com) has offices in Palo Alto, California, Shanghai, China, and Chengdu, China. 

 

 


'/>"/>
SOURCE Vivo Ventures, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Global Diagnostic Imaging Companies M&A, Joint Ventures, R&D Pipeline, and Strategies
2. PharmaSecure, an Innovator in Pharmaceutical Serialization, Closes $3.9M Investment by Eric Schmidts Innovation Endeavors, Gray Ghost Ventures, Healthtech Capital and the TEEC Angel Fund
3. USRBC President Ed Verona Lauds GE Announcement on Energy and Healthcare Joint Ventures in Russia
4. Allegra® and Survivor Winner Danni Boatwright Want to Hear About Your "Allergy Adventures"
5. Global Health Ventures August 4th Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
6. Global Health Ventures to Present Live, Online at RetailInvestorConferences.com on August 4th
7. PharmaVentures Engaged by Avexa to Assist in the Out-licensing of Apricitabine
8. Vivo Ventures Announces Promotions of Dr. Chen Yu and Dr. James Zhao to Managing Partner
9. XDATA Retains Adapt IP Ventures to Market Patents and Technology for Automated 3D Ultrasound Imaging System
10. Aethlon Medical to Present the Aethlon ADAPT™ System at C21 BioVentures™ Life Sciences Partnering Conference
11. JumpStart Ventures Invests in Cleveland-based SPR Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2017)... , January 16, 2017 Le ... innovants à base de collagène pour la régénération de tissus ... au poste de directeur général avec effet immédiat. ... Bill est un ... a occupé plusieurs postes de gestion générale et de direction ...
(Date:1/13/2017)... , Jan. 13, 2017 /PRNewswire/ - InMed Pharmaceuticals, Inc. ("InMed") (CSE: ... VP of Corporate Finance and Investment Banking at Eli Lilly ... effective immediately. Mr. Bott brings over 28 years of senior ... ... Martin Bott has established a significant leadership position in ...
(Date:1/13/2017)... York , January 13, 2017 ... prevalence of AIDS will collectively contribute to the demand for ... to reach a value of US$ 551.0 Mn by 2016 ... will remain the most lucrative markets for western blotting, whereas ... the market globally. ...
Breaking Medicine Technology:
(Date:1/16/2017)... , ... January 16, 2017 , ... ... attorney, science teacher, http://www.ageofautism.com/legal , Sharon Kleyne, America’s leading water educator, ... to her nationally syndicated radio program, The Sharon Kleyne Hour Power of Water, ...
(Date:1/16/2017)... PARK CITY, UT (PRWEB) , ... January 16, 2017 , ... ... expensive disease not only to treat, but to test for, as well. The money ... $88.7 billion every year.(1) Doctors in the U.S. screen patients for cancer more than ...
(Date:1/16/2017)... ... January 16, 2017 , ... NexTec Group has been selected as a ... honored for their accomplishments in the field of midmarket financial software. , Members of ... and innovation. Selection is not based on revenue and those firms chosen represent a ...
(Date:1/15/2017)... ... January 15, 2017 , ... Whole Health Supply, LLC is announcing the release of an updated ... avenues for purchase. , The 2017 edition has wide jaws that will accommodate nails ... boomers as well as diabetics. This handle is reinforced for extra strength when pressing down ...
(Date:1/15/2017)... ... January 15, 2017 , ... San ... in eight Bay Area counties for 2017. Almost 1,000 nominations were submitted and ... the award process. Results were announced the magazine’s January 2017 issue . ...
Breaking Medicine News(10 mins):